Word: fda
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...competition. "Zantac on the market will be a significant competitor," says Robert Kniffin, vice president of Johnson & Johnson's external communications. "We shall see." (As if Zantac 75's entry were not enough, another candidate in the same acid-blocker category, Eli Lilly's Axid, has also won tentative FDA approval for over-the-counter sale...
...earned the company a total of $14 billion and was the first drug ever to chalk up $1 billion in sales in a single year. But in the late 1980s, anticipating the worst when its Tagamet patent ran out in 1994, SmithKline began conducting clinical trials and seeking FDA approval of an over-the-counter version. The wisdom of that decision became evident when Tagamet sales plummeted from $600 million in 1993 to only $400 million last year after the drug lost its patent protection in May and became vulnerable to competition from less expensive generic varieties...
...Johnson & Johnson/Merck, producer of Pepcid, beat SmithKline to the punch. It won FDA approval of its over-the-counter version, Pepcid AC, and began marketing it in June. Between its introduction and August, when Tagamet HB first appeared in pharmacies, Pepcid AC gained a 22% share of the entire antacid market. "Pepcid had a window of opportunity, and it exploited it well in the marketplace," says Silvermine Consulting's Kelly. "That's an amazing accomplishment." Amazing, and expensive. J&J/Merck and SmithKline are each spending some $100 million in marketing campaigns for their new acid blockers...
...drug in the world and the pride of Britain's Glaxo-Wellcome pharmaceutical stable. Prescribed for 240 million patients around the globe, Zantac last year generated $3.6 billion in sales, $2.1 billion in the U.S. And last month the over-the-counter Zantac 75 received a recommendation from an FDA advisory committee, virtually assuring its imminent approval for sale...
...patented the drug, some company would have developed it and it would have needed FDA approval, Wurtman says. Then, when the manufacturer changed to the Japanese company, the FDA would have done new tests on the drug...